{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T07:18:15Z","timestamp":1762240695522,"version":"build-2065373602"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>A 77-year-old Chinese male with a 10-year history of plaque psoriasis had recurrent episodes of symmetric hypertrophic verrucous plaques in the lower legs. The patient was monitored for the evolution of the disease over two years before he came to our attention. Because the lesions were resistant to topical glucocorticoids and vitamin D3 at another dermatological center, the patient was treated with secukinumab for one year. However, the verrucous lesions further worsened, and the patient visited the outpatient department of our hospital in March 2023. Treatment with guselkumab was started. It immediately attenuated the plaques of the trunk and limbs. Surprisingly, the verrucous plaques of both legs showed complete resolution in 6 months.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1596544","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T07:13:08Z","timestamp":1762240388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Successful treatment of guselkumab in a patient with verrucous psoriasis unresponsive to secukinumab"],"prefix":"10.3389","volume":"16","author":[{"given":"Jianfeng","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1994.tb01423.x","article-title":"Psoriasis verrucosa showing peculiar histologic features","volume":"21","author":"Nakamura","year":"1994","journal-title":"J Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13243","article-title":"Psoriasis with verrucous appearance","volume":"55","author":"Baba","year":"2016","journal-title":"Int J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7241\/ourd.20171.17","article-title":"Psoriasis with verrucous appearance: A case report","volume":"8","author":"Ben Rejeb","year":"2017","journal-title":"Our Dermatol Online"},{"key":"B4","article-title":"A case of psoriasis verrucosa successfully treated with adalimumab","volume":"11","author":"Maejima","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R","volume":"168","author":"Parham","year":"2002","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0800-7","article-title":"Guselkumab: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.det.2014.09.002","article-title":"The immunopathogenesis of psoriasis","volume":"33","author":"Kim","year":"2015","journal-title":"Dermatol Clin"},{"key":"B8","article-title":"Verrucous psoriasis treated with methotrexate and acitretin combination therapy","volume":"104","author":"Shivers","year":"2019","journal-title":"Cutis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17402","article-title":"Emergence of verrucous psoriasis post-secukinumab therapy","volume":"52","author":"Zhixuan","year":"2025","journal-title":"J Dermal"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e2024032","DOI":"10.5826\/dpc.1401a32","article-title":"Unilateral verrucous psoriasis successfully treated with adalimumab","volume":"14","author":"Duarte","year":"2024","journal-title":"Dermatol Pract Concept"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14877","article-title":"Favorable response to apremilast in a patient with refractory psoriasis verrucosa","volume":"46","author":"Okazaki","year":"2019","journal-title":"J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1596544\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T07:13:10Z","timestamp":1762240390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1596544\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":11,"alternative-id":["10.3389\/fimmu.2025.1596544"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1596544","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"article-number":"1596544"}}